We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Growth Seen for European POC Coagulation Testing

By HospiMedica staff writers
Posted on 15 Dec 2003
The point-of-care (POC) testing market in Europe will grow from 140 million euros in 2003 to more than 350 million euros in 2009, according to a new analysis from international consultants Frost & Sullivan (London, UK). More...
This figure includes near-testing and self-testing devices. The growth is being fostered by the clinical results and the lower costs of an increasing number of outpatient anticoagulation clinics.

POC coagulation analyzers are gaining preference in the critical care, surgery, and home testing environments, since they provide rapid and accurate information for improved patient monitoring. Coagulation testing looks at endpoint measurements between bleeding and clotting, and the new technologic developments are expected to allow a comprehensive assessment of the complex interactions between various blood clotting factors.

"The biggest advantage of POC testing is the decrease in turn-around time because most POC analyses are performed on whole blood, minimizing any transport and logistic handovers that normally occur within laboratory testing,” explained Shree Viswadia, a research analyst with Frost & Sullivan.

Market concerns include slow implementation of insurance reimbursement and the development of new thrombin inhibitor drugs that could gradually eliminate the need for routine testing. Nonetheless, POC testing is finding increasing acceptance across Europe, with Germany, Italy, and the United Kingdom having the largest number of users.




Related Links:
Frost & Sullivan >>

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automatic CLIA Analyzer
Shine i6000
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.